» Articles » PMID: 23044729

Ultrasound Joint Inflammation in Rheumatoid Arthritis in Clinical Remission: How Many and Which Joints Should Be Assessed?

Abstract

Objective: To investigate the sensitivity for detecting subclinical synovitis of different reduced joint ultrasound (US) assessment models as compared with a comprehensive US assessment in rheumatoid arthritis (RA) patients in clinical remission.

Methods: Sixty-seven RA patients (50 women, 17 men) in clinical remission as judged by their consultant rheumatologist and treated with methotrexate were prospectively recruited. Patients were evaluated for disease activity according to the Disease Activity Score in 28 joints (DAS28) and the Simplified Disease Activity Index (SDAI) by the same investigator. Each patient underwent a 44-joint B-mode and power Doppler (PD) assessment by a rheumatologist blinded to the clinical and laboratory data. B-mode synovial hypertrophy (SH) and synovial PD signal were scored from 0-3 at each joint. Global indices for SH and PD signal were calculated for the 44-joint and different joint combination models for each patient.

Results: SH was detected in 87.8% of patients with a DAS28 <2.6 and in 81.8% of patients with an SDAI <3.3. Synovial PD signal was detected in 46.3% of patients with a DAS28 <2.6 and in 36.4% of patients with an SDAI <3.3. Wrist, second through fifth metacarpophalangeal (MCP), ankle, and second through fifth metatarsophalangeal (MTP) joint and 12-joint US assessments showed the highest correlations with the comprehensive US assessment. The wrist, MCP, ankle, and MTP joint US assessment showed the highest sensitivity for detecting SH and synovial PD signal in patients in remission according to the DAS28 and SDAI as compared to the comprehensive US assessment.

Conclusion: US assessment of the wrist, MCP, ankle, and MTP joints can be highly sensitive for detecting residual B-mode and Doppler joint inflammation in RA patients.

Citing Articles

Prediction of long-term drug-free outcomes in ACPA-positive and ACPA-negative rheumatoid arthritis by combined clinical and ultrasound assessment of residual disease: a 5-year prospective study.

Manzo A, Bozzalla Cassione E, Montecucco C, Sakellariou G, Xoxi B, Luvaro T RMD Open. 2025; 11(1).

PMID: 39880410 PMC: 11781140. DOI: 10.1136/rmdopen-2024-005079.


Biomarkers in the diagnosis, prognosis and management of rheumatoid arthritis: A comprehensive review.

Sahin D, Di Matteo A, Emery P Ann Clin Biochem. 2024; 62(1):3-21.

PMID: 39242085 PMC: 11707974. DOI: 10.1177/00045632241285843.


Clinical and Ultrasonographic Remission in Bio-naïve and Bio-failure Patients with Rheumatoid Arthritis at 24 Weeks of Upadacitinib Treatment: The UPARAREMUS Real-Life Study.

Picchianti Diamanti A, Cattaruzza M, Salemi S, Di Rosa R, Sesti G, De Lorenzo C Rheumatol Ther. 2024; 11(5):1347-1361.

PMID: 39177745 PMC: 11422397. DOI: 10.1007/s40744-024-00712-y.


Machine learning-based prediction of relapse in rheumatoid arthritis patients using data on ultrasound examination and blood test.

Matsuo H, Kamada M, Imamura A, Shimizu M, Inagaki M, Tsuji Y Sci Rep. 2022; 12(1):7224.

PMID: 35508670 PMC: 9068780. DOI: 10.1038/s41598-022-11361-y.


A Pragmatic Application of Ultrasonography for the Assessment of Disease Activity in Patients with Early Inflammatory Arthritis.

Nam S, Kang T J Clin Med. 2021; 10(2).

PMID: 33466710 PMC: 7828798. DOI: 10.3390/jcm10020283.